Ortin Global Limited (ORTINGLOBE)

Loading page…

Ortin Global Limited (ORTINGLOBE) · mywealthgrid

About

Ortin Global Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹12 Cr

P/E

—

P/B

9.5×

Dividend yield

ROE

-46%

ROCE

-32.7%

Debt / equity

0.81

OPM

—

EPS (TTM)

₹-1.1

Book value

₹1.5

52-week high

—

52-week low

—

1,358 historical price candles were omitted because the exchange source has not been verified.

₹14.5-1.4%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -66.3% (3-yr avg)
−Revenue shrank over the last 5 years (-58.5% a year)
−Trading at 9.5× book value
−Low promoter holding of 1.2%

Research score

Structured signal from quality, growth, valuation and momentum.

27/100

Business quality: 20
Growth: 0
Valuation: 61

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	58	80	168	197	8	8	6	2	0	0
COGS	—	-58	-136	-155	4	5	3	4	0	0
Gross profit	—	—	—	—	4	4	3	-2	0	0
	57	132	298	346	3	3	2	5	1	1
	1	5	6	6	1	0	1	-7	-1	-1
OPM %	2.1%	6.8%	3.7%	2.9%	15.3%	4.5%	8.6%	-310%	-261.8%	—
Depreciation	2	2	—	2	0	0	0	0	0	0
Interest	3	3	3	3	1	1	0	0	0	0
	4	0	0	0	0	0	0	0	0	0
Profit before tax	1	1	2	1	0	-1	-0	-7	-1	-1
Tax	1	-0	1	1	-1	-0	-0	1	0	0
Tax %	62.4%	-18.8%	28.3%	179.2%	-578.6%	-24.5%	-25%	13.7%	1.2%	2.8%
	0	1	1	-1	1	-0	-0	-8	-1	-1
PAT margin %	0.7%	1%	0.8%	-0.3%	11.6%	-4.9%	-1.2%	-381%	-250%	-740%
EPS (₹)	0.2	0.5	—	-0.3	1.2	-0.5	-0.1	-9.9	-1	-0.9
EPS adjusted (₹)	—	0.5	0.8	-0.3	1.2	-0.5	-0.1	-9.9	-1.1	-0.9
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	17	17	17	8	8	8	8	8	8
Reserves	7	8	7	—	3	3	-5	-6	-7
	16	19	20	—	6	6	2	0	1
	33	61	73	—	4	4	2	2	2
Total equity & liabilities	74	105	117	—	21	21	7	4	5
	20	21	22	14	14	14	0	0	0
CWIP	0	—	—	—	0	0	—	—	0
Investments	0	0	0	—	0	0	0	0	0
	53	84	94	—	6	7	7	4	5
Total assets	74	105	117	—	21	21	7	4	5

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	51.7%	43.4%	43.7%	-75.8%	38.2%	0%
EBITDA margin %	3.7%	2.9%	15.3%	4.5%	8.6%	-310%	-261.8%	-1,040%
EBIT margin %	3.7%	1.9%	11.8%	1%	4.5%	-320.9%	-264.7%	-1,040%
PAT margin %	0.8%	-0.3%	11.6%	-4.9%	-1.2%	-381%	-250%	-740%
Working capital
Receivable days	82	69	—	144	207	306	279	730
Inventory days	84	95	—	136	280	5	35	0
Payable days	108	114	—	62	167	8	70	146
NWC days	58	49	—	218	320	303	244	584
Leverage
Current ratio	1.14	1.1	—	0.76	0.94	3.11	2.39	1.59
Debt to EBITDA	3.12	3.43	—	16.62	12.38	—	—	—
Debt to equity	0.78	0.82	—	0.56	0.59	0.64	0.13	0.81
Interest coverage	2	1.2	1.2	0.3	0.8	-13.8	—	—
Asset turnover	1.6	1.69	—	0.4	0.28	0.32	0.09	0.02
Return ratios
Return on assets %	1.3%	-0.5%	—	-1.9%	-0.3%	-122%	-22.5%	-15.9%
Return on capital employed %	12%	12%	—	2.1%	2.3%	-70.3%	-25.4%	-32.7%
Return on equity %	5.3%	-2.4%	—	-3.6%	-0.6%	-285.1%	-42.9%	-59.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	7.37%	7.36%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%
	0%	0%	0%	6.25%	6.25%	6.25%	6.53%	6.53%	1.68%	1.68%	1.68%	1.8%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	92.63%	92.64%	98.77%	92.52%	92.52%	92.52%	92.24%	92.24%	97.09%	97.09%	97.09%	96.97%
No. of shareholders	—	—	—	—	—	—	—	—	12,060	11,834	11,452	11,383

Promoter holding down 6.14 percentage points since Sep 2023.

61 deals · 14 Dec 2021 – 10 Jul 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
10 Jul 2026	WAVE CAPITAL LTD	Bulk	NSE	Sell	50,000	₹16.24	₹0.08 Cr
8 Jun 2026	KUMARI ARUNIMA	Bulk	NSE	Buy	50,000	₹19.81	₹0.10 Cr
24 Feb 2026	MIR ATA ALI KHAN	Bulk	NSE	Buy	46,000	₹17.97	₹0.08 Cr
20 Feb 2026	NEO APEX VENTURE LLP	Bulk	NSE	Sell	51,773	₹19.90	₹0.10 Cr
20 Feb 2026	VIVEK KANDA	Bulk	NSE	Buy	50,000	₹19.87	₹0.10 Cr
20 Feb 2026	SHIVAM OMAR	Bulk	NSE	Sell	48,798	₹19.90	₹0.10 Cr
20 Feb 2026	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	NSE	Sell	43,054	₹19.88	₹0.09 Cr
20 Feb 2026	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	NSE	Buy	17,500	₹19.90	₹0.03 Cr
20 Feb 2026	SHIVAM OMAR	Bulk	NSE	Buy	9,184	₹18.64	₹0.02 Cr
8 Aug 2025	SUBHASH LALITPRASAD YADAV	Bulk	NSE	Buy	1,00,000	₹17.00	₹0.17 Cr

1–10 of 61

1 / 7

Mr. SARANG BALBHIMRAO PATODEKARNon-Executive - Independent Director-Chairperson
Mr. MURALI KRISHNA MURTHY SANKAExecutive Director-MD
Mr. PRASHANT PRAKASH SAWANTExecutive Director
Mr. AJAY VISHWAKARMANon-Executive - Independent Director
Mr. PRAMOD DNYANDEO WAGHENon-Executive - Non Independent Director
Mrs. PRAKRUTI PRASHANT SAWANTExecutive Director
Mrs. MOUNIKA PAMMINon-Executive - Independent Director
Mr. Wani Rahul MadanlalChief Financial Officer
Mrs. Madhu Mala SolankiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Ortin Global Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

13 announcementsExport CSV

14 Aug 2026, 7:53 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting Held On 14.08.2026

Outcome of Board Meeting PDF

14 Aug 2026, 7:48 pmResult

Unaudited Financial Results For The Quarter Ended 30.06.2026

Financial Results PDF

7 Aug 2026, 4:58 pmBoard Meeting

Board Meeting Intimation for Meeting To Be Held On 14.08.2026

Exchange filing PDF

11 Jul 2026, 4:18 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

11 Jul 2026, 9:08 amCompany Update

Post-Offer Advertisement

General PDF

Date	Category	Subject	Filing
14 Aug 2026, 7:53 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting Held On 14.08.2026	PDF
14 Aug 2026, 7:48 pm	Result Financial Results	Unaudited Financial Results For The Quarter Ended 30.06.2026

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	51.7%	43.4%	43.7%	-75.8%	38.2%	0%
EBITDA margin %	3.7%	2.9%	15.3%	4.5%	8.6%	-310%	-261.8%	-1,040%
EBIT margin %	3.7%	1.9%	11.8%	1%	4.5%	-320.9%	-264.7%	-1,040%
PAT margin %	0.8%	-0.3%	11.6%	-4.9%	-1.2%	-381%	-250%	-740%
Working capital
Receivable days	82	69	—	144	207	306	279	730
Inventory days	84	95	—	136	280	5	35	0
Payable days	108	114	—	62	167	8	70	146
NWC days	58	49	—	218	320	303	244	584
Leverage
Current ratio	1.14	1.1	—	0.76	0.94	3.11	2.39	1.59
Debt to EBITDA	3.12	3.43	—	16.62	12.38	—	—	—
Debt to equity	0.78	0.82	—	0.56	0.59	0.64	0.13	0.81
Interest coverage	2	1.2	1.2	0.3	0.8	-13.8	—	—
Asset turnover	1.6	1.69	—	0.4	0.28	0.32	0.09	0.02
Return ratios
Return on assets %	1.3%	-0.5%	—	-1.9%	-0.3%	-122%	-22.5%	-15.9%
Return on capital employed %	12%	12%	—	2.1%	2.3%	-70.3%	-25.4%	-32.7%
Return on equity %	5.3%	-2.4%	—	-3.6%	-0.6%	-285.1%	-42.9%	-59.7%

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2	2	7	6	18	2	-0	-4	-0	-1
	-1	-1	-3	-3	0	-0	0	12	0	0
	-1	0	-3	-4	-8	-0	1	-3	0	1
Net cash flow	-0	1	0	-1	10	2	1	4	-0	0
Free cash flow	1	0	4	3	18	2	-0	-4	-0	-1
CFO / Operating profit %	159%	28.9%	104.3%	109.1%	—	581.1%	-42.3%	—	—	—

Ortin Global Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1